Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
3
result(s) for
"V M, Bala Murali"
Sort by:
Understanding the action of bamocaftor as a potential drug candidate against Cystic Fibrosis Transmembrane Regulator protein: A computational approach
by
Patel, Naisarg
,
Thiruselvam, Premkumar
,
V M, Bala Murali
in
Aminophenols - chemistry
,
Aminophenols - pharmacology
,
Biology and Life Sciences
2025
Cystic Fibrosis (CF) is a hereditary condition and can cause permanent respiration problems leading to degraded life quality. The most common variation leading to CF is the F508del variation. CF can cause damage to not just the lungs but also digestive system, pancreas, and other organs. CF decreases the life expectancy of the individuals affected with the constant fear of lung complications. The current methods of treatment include using a combination of drugs to manage the symptoms. The combination of drugs has many side effects and causes damage to other organs like liver, heart or kidneys. In this study, we aim to find a drug that can relieve the symptoms of CF. We began by creating a dataset of potential drug molecules, which was subsequently refined by removing harmful compounds through an ADMET scan. All these compounds were then docked to the mutated Cystic Fibrosis Transmembrane Regulator (CFTR) protein. The compounds with the best docking affinity were Galicaftor and Bamocaftor. A currently approved drug, Ivacaftor was selected as control for the 200 ns Molecular Dynamics (MD) Simulation. The simulation revealed that the CFTR protein remained more stable and compact when complexed with Bamocaftor, when compared to Ivacaftor and Galicaftor. Moreover, the MMPBSA free energy calculations revealed that the free energy of the CFTR-bamocaftor complex is the lowest compared to the other complexes. Our findings reveal the action of bamocaftor on CFTR protein with p.Phe508del variation. However, the absence of in-vivo or in-vitro studies is a limitation, and further experimental validation is necessary to confirm its efficacy and safety.
Journal Article
Understanding the action of bamocaftor as a potential drug candidate against Cystic Fibrosis Transmembrane Regulator protein: A computational approach
2025
Cystic Fibrosis (CF) is a hereditary condition and can cause permanent respiration problems leading to degraded life quality. The most common variation leading to CF is the F508del variation. CF can cause damage to not just the lungs but also digestive system, pancreas, and other organs. CF decreases the life expectancy of the individuals affected with the constant fear of lung complications. The current methods of treatment include using a combination of drugs to manage the symptoms. The combination of drugs has many side effects and causes damage to other organs like liver, heart or kidneys. In this study, we aim to find a drug that can relieve the symptoms of CF. We began by creating a dataset of potential drug molecules, which was subsequently refined by removing harmful compounds through an ADMET scan. All these compounds were then docked to the mutated Cystic Fibrosis Transmembrane Regulator (CFTR) protein. The compounds with the best docking affinity were Galicaftor and Bamocaftor. A currently approved drug, Ivacaftor was selected as control for the 200 ns Molecular Dynamics (MD) Simulation. The simulation revealed that the CFTR protein remained more stable and compact when complexed with Bamocaftor, when compared to Ivacaftor and Galicaftor. Moreover, the MMPBSA free energy calculations revealed that the free energy of the CFTR-bamocaftor complex is the lowest compared to the other complexes. Our findings reveal the action of bamocaftor on CFTR protein with p.Phe508del variation. However, the absence of in-vivo or in-vitro studies is a limitation, and further experimental validation is necessary to confirm its efficacy and safety.
Journal Article
Modelling and fabrication of ACHM-Arduino Controlled Humanoid Manipulator
2025
The development of a humanoid manipulator using embedded software focuses on creating a robotic system that mimics human-like movements and interactions through the integration of hardware and software. The robot features a lightweight frame driven by servomotors at the joints. An Arduino microcontroller coordinates the movements of these servos to execute a simple walking gait. The control system is based on pre-programmed step sequences that ensure smooth motion and balance. The fabrication process involves constructing the mechanical structure, wiring the servos, and programming the Arduino. The manipulator demonstrates basic walking functionality, providing a foundation for future advancements in humanoid robotics and gait control. Primarily focusses on the design and modelling using SolidWorks and later the fabrication process involves assembling the robot’s physical components, including the frame and servos, followed by wiring the servos to the Arduino and loading the necessary code onto the microcontroller. The Arduino is programmed with Software that control the timing and sequence of servo movements, enabling the robot to take steps forward, mimic a walking pattern, and maintain basic stability and also includes an ultrasonic sensor which senses the frequencies and greets the way one needed based on different voice commands given, record. The position of the end effector was studied using the forward kinematics and the torque applied has been calculated.
Journal Article